InVivo Therapeutics Holdings Corp. (NVIV) today announced that
the role of Christopher McNulty has been expanded to include investor
relations and corporate communications. Mr. McNulty has been serving as
Vice President, Business Development, and will continue to lead efforts
in that area.
This move is part of an expanded commitment to InVivo’s outreach to
existing investors, new potential institutional investors, the spinal
cord injury (SCI) community, and the general public. With a strong
management team in place, an on-going first-in-human clinical trial, and
a streamlined strategic focus on developing effective therapies for
spinal cord injury, InVivo expects to have a steady flow of news over
the coming year. Mr. McNulty will lead an integrated corporate
communications effort that will include investor relations, public
relations, medical/scientific communications, and patient advocacy.
Before coming to InVivo, Mr. McNulty served as Senior Director of
Business Development at Repligen Corporation, where his responsibilities
included out-licensing programs for rare neurodegenerative diseases.
Previously, he was Director of Corporate Development at Seventh Sense
Biosystems and Associate Director of Business Development and Alliance
Management at Genzyme Corporation. Mr. McNulty has also held technical
roles at Transform Pharmaceuticals and Cereon Genomics. He has an MBA
from Harvard Business School, and BS and MEng degrees from MIT.
Mark Perrin, InVivo’s Chief Executive Officer, said, “Combining our
investor relations, public relations, medical communications, and
patient advocacy efforts into a comprehensive and synergistic corporate
communications function will improve our communication efforts to all
our constituents. We have engaged excellent partners with expertise in
each of these areas to assist us in our efforts, and I look forward to
our future activities.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and
biotechnology company with a focus on treatment of spinal cord injuries.
The company was founded in 2005 with proprietary technology co-invented
by Robert Langer, ScD., Professor at Massachusetts Institute of
Technology, and Joseph P. Vacanti, M.D., who is affiliated with
Massachusetts General Hospital. In 2011 the Company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. The publicly
traded company is headquartered in Cambridge, MA. For more details,
visit, www.invivotherapeutics.com.
Copyright Business Wire 2014